[go: up one dir, main page]

NO20004917D0 - Farmasøytika for avbildning av angiogene mangler - Google Patents

Farmasøytika for avbildning av angiogene mangler

Info

Publication number
NO20004917D0
NO20004917D0 NO20004917A NO20004917A NO20004917D0 NO 20004917 D0 NO20004917 D0 NO 20004917D0 NO 20004917 A NO20004917 A NO 20004917A NO 20004917 A NO20004917 A NO 20004917A NO 20004917 D0 NO20004917 D0 NO 20004917D0
Authority
NO
Norway
Prior art keywords
pharmaceuticals
deficiencies
imaging angiogenic
angiogenic
imaging
Prior art date
Application number
NO20004917A
Other languages
English (en)
Other versions
NO20004917L (no
Inventor
Miland Rajopadhye
D Scott Edwards
Thomas David Harris
Stuart J Heminway
Shuang Liu
Prahlad R Singh
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20004917D0 publication Critical patent/NO20004917D0/no
Publication of NO20004917L publication Critical patent/NO20004917L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20004917A 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler NO20004917L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US11271598P 1998-12-18 1998-12-18
PCT/US1999/006826 WO1999058162A2 (en) 1998-03-31 1999-03-29 Pharmaceuticals for the imaging of angiogenic disorders

Publications (2)

Publication Number Publication Date
NO20004917D0 true NO20004917D0 (no) 2000-09-29
NO20004917L NO20004917L (no) 2000-11-02

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004917A NO20004917L (no) 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler

Country Status (20)

Country Link
US (2) US20020001566A1 (no)
EP (1) EP1068224B1 (no)
JP (1) JP4487019B2 (no)
KR (1) KR20010042288A (no)
CN (1) CN1295578A (no)
AR (1) AR020586A1 (no)
AT (1) ATE295369T1 (no)
AU (1) AU5541799A (no)
BR (1) BR9909420A (no)
CA (1) CA2324555A1 (no)
DE (1) DE69925262T2 (no)
EA (1) EA200001007A1 (no)
EE (1) EE200000574A (no)
ES (1) ES2241313T3 (no)
HU (1) HUP0101468A2 (no)
IL (1) IL138093A0 (no)
NO (1) NO20004917L (no)
PL (1) PL343804A1 (no)
SK (1) SK13952000A3 (no)
WO (1) WO1999058162A2 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1281068B1 (en) * 2000-05-08 2008-03-26 TTP LabTech Ltd Microphysiometer
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2410887C (en) 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
CA2429956A1 (en) 2000-11-27 2002-07-18 Alan P. Carpenter, Jr. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1381396B1 (en) 2001-04-23 2009-04-01 Mallinckrodt Inc. Tc and re labeled radioactive glycosylated octreotide derivatives
CA2452478A1 (en) * 2001-08-08 2003-02-20 Bristol-Myers Squibb Pharma Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
US7255875B2 (en) 2002-01-24 2007-08-14 Barnes-Jewish Hospital Integrin targeted imaging agents
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP2301587B1 (en) * 2002-03-01 2014-06-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
CN1653297B (zh) * 2002-05-08 2010-09-29 佛森技术公司 高效固态光源及其使用和制造方法
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20040122354A1 (en) * 2002-09-05 2004-06-24 Semba Charles P. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
EP1539804B1 (fr) * 2002-09-19 2007-01-03 Centre National De La Recherche Scientifique (Cnrs) Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles.
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
EP1622647B1 (en) * 2003-05-12 2009-11-25 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
JP2007501797A (ja) * 2003-08-08 2007-02-01 バーンズ−ジューイッシュ ホスピタル 造影及び治療用エマルジョン粒子並びにその使用方法
WO2005016387A2 (en) * 2003-08-12 2005-02-24 University Of Iowa Research Foundation Dna-dependent mri contrast agents
WO2005077407A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
JP2007523248A (ja) * 2004-02-23 2007-08-16 ダウ グローバル テクノロジーズ インコーポレイティド 低表面エネルギー基体接着用水性接着剤
WO2005122891A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
DE602005000853D1 (de) * 2004-07-02 2007-05-24 Vivactis Nv Messung der Wärme erzeugt durch einen chemischen oder biologischen Prozess.
JP2008538204A (ja) * 2005-03-10 2008-10-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化側鎖を含む放射性標識複合体キレート剤
CA2606479A1 (en) * 2005-04-29 2006-11-09 Wyeth Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
CA2630415A1 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
US20070140973A1 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
CA2650574A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
AU2007303465A1 (en) * 2006-09-29 2008-04-10 Washington University Combinations for treatment of neovasculature
US20100016706A1 (en) * 2006-12-08 2010-01-21 Molecular Image, Inc. Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
AU2014241182A1 (en) * 2013-03-27 2015-09-24 Theranos Ip Company, Llc Biological sample processing
US11274139B2 (en) * 2013-04-12 2022-03-15 Evox Therapeutics Ltd Therapeutic delivery vesicles
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물
US12377166B2 (en) * 2021-08-26 2025-08-05 University Of Washington Iron oxide nanoparticle for targeted chemo-immunotherapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
EP0086627B1 (en) 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
EP0534944B1 (en) 1988-11-14 1996-09-11 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
IL112768A (en) 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
AU638043B2 (en) 1989-07-20 1993-06-17 Novartis Ag Labeled polypeptide derivatives
IN172208B (no) 1990-04-02 1993-05-01 Sint Sa
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
JPH09500140A (ja) 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド Ｎ▲下３▼ｓ立体配置を有するヒドラジノ型放射性核種キレート形成剤
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
WO1996001653A1 (en) 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
JPH11510814A (ja) 1995-08-30 1999-09-21 ジー．ディー．サール アンド カンパニー インテグリンアンタゴニストとしてのメタ−グアニジン、尿素、チオ尿素またはアザ環状アミノ安息香酸誘導体
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
ATE243230T1 (de) * 1995-11-01 2003-07-15 Bracco Research Sa Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel
HUP0201479A2 (en) 1995-11-14 2002-08-28 Bristol Myers Squibb Pharma Co Novel macrocyclic compounds as metalloprotease inhibitors and pharmaceutical compositions containing them
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016256A1 (en) * 1996-10-16 1998-04-23 The Burnham Institute Magnetic resonance imaging of thrombi
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP0946202B1 (en) 1996-10-28 2003-09-10 Amersham Health AS Contrast agents
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
DE69839844D1 (de) * 1997-09-10 2008-09-18 Burnham Inst Verfahren zur auffindung von zielsuchenden verbindungen spezifisch für angiogenese vaskulatur
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
EP1100506A4 (en) 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
IL138093A0 (en) 2001-10-31
EP1068224A2 (en) 2001-01-17
AR020586A1 (es) 2002-05-22
DE69925262D1 (de) 2005-06-16
ATE295369T1 (de) 2005-05-15
CN1295578A (zh) 2001-05-16
JP2002514611A (ja) 2002-05-21
ES2241313T3 (es) 2005-10-16
CA2324555A1 (en) 1999-11-18
WO1999058162A3 (en) 2000-04-06
EP1068224B1 (en) 2005-05-11
NO20004917L (no) 2000-11-02
KR20010042288A (ko) 2001-05-25
PL343804A1 (en) 2001-09-10
HUP0101468A2 (hu) 2001-08-28
WO1999058162A2 (en) 1999-11-18
EA200001007A1 (ru) 2001-04-23
US20020001566A1 (en) 2002-01-03
AU5541799A (en) 1999-11-29
SK13952000A3 (sk) 2001-12-03
BR9909420A (pt) 2001-09-25
EE200000574A (et) 2002-10-15
US6322770B1 (en) 2001-11-27
JP4487019B2 (ja) 2010-06-23
DE69925262T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
NO20004917L (no) Farmasøytika for avbildning av angiogene mangler
DE69837480D1 (de) Dynamische echtzeit-bildrekonstruktion
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE69926878D1 (de) Optoakustisches bildgebungssystem
DE69941532D1 (de) Bildaufnahmesystem
DE60038155D1 (de) Röntgenbildsystem
DK1011413T3 (da) Speculum
DE69918109D1 (de) Haarwaschmittel
NO20010046L (no) Dolastatin-15-derivater
NO992339L (no) Farmasöytiske formuleringer
NO20000231D0 (no) Dolastatin-15-derivater
DK1466615T3 (da) Farmaceutisk præparat
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
DE69715175D1 (de) Bilderzeugung
DE69906880D1 (de) Bilderzeugungsverfahren
NO20010089D0 (no) Farmasöytisk levotyroksinpreparat
NO983828D0 (no) Kontrastmiddel
DE69926012D1 (de) Arzneizubereitungen
DE60017700D1 (de) Bildgebungsverfahren
NO20016430L (no) Farmasöytisk kompleks
DE69906934D1 (de) Arzneizubereitungen
DE59804561D1 (de) Lippenrollvorrichtung
FI991137L (fi) Laite ja järjestely oftalmoskopiaa varten
DK199801743A (da) Sum-intervaldetektor
DK1189600T3 (da) GRF-holdige lyofiliserede farmaceutiske præparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application